Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | MLNR | O43193 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4584828 | 1.00 | SIGMAR1 (0.52) | SIGMAR1ALDH1A1SMN1; SMN2CHRM2CHRM4 | |
| SCHEMBL4596584 | 1.00 | SIGMAR1 (0.52) | SIGMAR1ALDH1A1SMN1; SMN2CHRM2CHRM4 | |
| SCHEMBL18411348 | 0.84 | SIGMAR1 (0.53) | SIGMAR1MEN1KMT2A | |
| SCHEMBL14460139 | 0.83 | SIGMAR1 (0.52) | SIGMAR1ALDH1A1KMT2A | |
| SCHEMBL13936121 | 0.83 | SIGMAR1 (0.52) | SIGMAR1ALDH1A1KMT2A | |
| SCHEMBL14401346 | 0.82 | SIGMAR1 (0.56) | SIGMAR1ALDH1A1MLNR | |
| SCHEMBL5058871 | 0.82 | SIGMAR1 (0.56) | SIGMAR1ALDH1A1MLNR | |
| SCHEMBL3165725 | 0.82 | SIGMAR1 (0.56) | SIGMAR1ALDH1A1MLNR | |
| SCHEMBL4678046 | 0.82 | SIGMAR1 (0.56) | SIGMAR1ALDH1A1MLNR | |
| SCHEMBL5060895 | 0.82 | SIGMAR1 (0.56) | SIGMAR1ALDH1A1MLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210220349-A1 | DELTA OPIOID AGONIST, MU OPIOID ANTAGONIST COMPOSITIONS AND METHODS FOR TREATING PARKINSONS DISEASE | DMK PHARMACEUTICALS CORPORATION | 2021-07-22 | — | — | US | disclosed |
| US-10973815-B2 | Delta opioid agonist mu opioid antagonist compositions and methods for treating Parkinsons disease | VERSI GROUP, LLC (US) | 2021-04-13 | — | — | US | disclosed |
| US-20190038620-A1 | DELTA OPIOID AGONIST MU OPIOID ANTAGONIST COMPOSITIONS AND METHODS FOR TREATING PARKINSONS DISEASE | DMK PHARMACEUTICALS CORPORATION | 2019-02-07 | — | — | US | disclosed |
| EP-3436013-A1 | DELTA OPIOID AGONIST, MU OPIOID ANTAGONIST COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE | Versi Group, LLC (US) | 2019-02-06 | — | — | EP | disclosed |
| US-10071093-B2 | Method of treating Parkinson's Disease with a diarylmethylpiperazine compounds exhibiting delta opioid receptor agonist activity | VERSI GROUP, LLC (US) | 2018-09-11 | — | — | US | disclosed |
| US-20170290823-A1 | METHOD OF TREATING PARKINSON'S DISEASE WITH A DIARYLMETHYLPIPERAZINE COMPOUNDS EXHIBITING DELTA OPIOID RECEPTOR AGONIST ACTIVITY | DMK PHARMACEUTICALS CORPORATION | 2017-10-12 | — | — | US | disclosed |
| WO-2017173067-A1 | DELTA OPIOID AGONIST, MU OPIOID ANTAGONIST COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE | VERSI GROUP, LLC (US) | 2017-10-05 | — | — | WO | disclosed |
| WO-2017173067-A1 | DELTA OPIOID AGONIST, MU OPIOID ANTAGONIST COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE | VERSI GROUP, LLC (US) | 2017-10-05 | — | — | WO | disclosed |
| US-9701645-B2 | Method of treating Parkinson's disease with a diarylmethylpiperazine compounds exhibiting delta opioid receptor agonist activity | VERSI GROUP, LLC (US) | 2017-07-11 | — | — | US | disclosed |
| US-20140315922-A1 | METHOD OF TREATING PARKINSON'S DISEASE WITH A DIARYLMETHYLPIPERAZINE COMPOUNDS EXHIBITING DELTA OPIOID RECEPTOR AGONIST ACTIVITY | VERSI GROUP, LLC (US) | 2014-10-23 | — | — | US | disclosed |
| US-8642599-B2 | Method of treating Parkinson's Disease with diarylmethylpiperazine compounds exhibiting delta receptor agonist activity | VERSI GROUP, LLC (US) | 2014-02-04 | — | — | US | disclosed |
| US-8476280-B2 | Modulate contraction, relaxation of muscles | VERSI GROUP, LLC (US) | 2013-07-02 | — | — | US | disclosed |
| US-7683168-B2 | Compositions of novel opioid compounds and method of use thereof | Mount Cook Bio Sciences, Inc. (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683168-B2 | Compositions of novel opioid compounds and method of use thereof | Mount Cook Bio Sciences, Inc. (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683168-B2 | Compositions of novel opioid compounds and method of use thereof | Mount Cook Bio Sciences, Inc. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20070066625-A1 | METHOD OF TREATING PARKINSON'S DISEASE WITH DIARYLMETHYLPIPERAZINE COMPOUNDS EXHIBITING DELTA RECEPTOR AGONIST ACTIVITY | DMK PHARMACEUTICALS CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20070043028-A1 | Compositions of novel opioid compounds and method of use thereof | DMK PHARMACEUTICALS CORPORATION | 2007-02-22 | — | — | US | disclosed |
| US-20070043028-A1 | Compositions of novel opioid compounds and method of use thereof | DMK PHARMACEUTICALS CORPORATION | 2007-02-22 | — | — | US | disclosed |
| US-20070043028-A1 | Compositions of novel opioid compounds and method of use thereof | DMK PHARMACEUTICALS CORPORATION | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10973815-B2 | Delta opioid agonist mu opioid antagonist compositions and methods for treating Parkinsons disease | OPRD1, OPRK1, OPRM1 | SIGMAR1 13/4885ALDH1A1 2024/4885SMN1; SMN2 251/4885 |
| US-20170290823-A1 | METHOD OF TREATING PARKINSON'S DISEASE WITH A DIARYLMETHYLPIPERAZINE COMPOUNDS EXHIBITING DELTA OPIOID RECEPTOR AGONIST ACTIVITY | OPRD1, OPRM1, OPRK1 | SIGMAR1 9/4885ALDH1A1 2179/4885SMN1; SMN2 386/4885 |
| US-20190038620-A1 | DELTA OPIOID AGONIST MU OPIOID ANTAGONIST COMPOSITIONS AND METHODS FOR TREATING PARKINSONS DISEASE | OPRD1, OPRK1, OPRM1 | SIGMAR1 13/4885ALDH1A1 2024/4885SMN1; SMN2 251/4885 |
| US-10071093-B2 | Method of treating Parkinson's Disease with a diarylmethylpiperazine compounds exhibiting delta opioid receptor agonist activity | OPRD1, OPRM1, OPRK1 | SIGMAR1 9/4885ALDH1A1 2179/4885SMN1; SMN2 386/4885 |
| US-20070043028-A1 | Compositions of novel opioid compounds and method of use thereof | OPRL1, OPRD1, OPRK1 | SIGMAR1 5/4885ALDH1A1 3383/4885SMN1; SMN2 1087/4885 |
| US-20140315922-A1 | METHOD OF TREATING PARKINSON'S DISEASE WITH A DIARYLMETHYLPIPERAZINE COMPOUNDS EXHIBITING DELTA OPIOID RECEPTOR AGONIST ACTIVITY | OPRD1, OPRM1, OPRK1 | SIGMAR1 9/4885ALDH1A1 2179/4885SMN1; SMN2 386/4885 |
| US-20210220349-A1 | DELTA OPIOID AGONIST, MU OPIOID ANTAGONIST COMPOSITIONS AND METHODS FOR TREATING PARKINSONS DISEASE | OPRD1, OPRK1, OPRM1 | SIGMAR1 13/4885ALDH1A1 2158/4885SMN1; SMN2 225/4885 |
| US-20070066625-A1 | METHOD OF TREATING PARKINSON'S DISEASE WITH DIARYLMETHYLPIPERAZINE COMPOUNDS EXHIBITING DELTA RECEPTOR AGONIST ACTIVITY | OPRD1, OPRM1, OPRK1 | SIGMAR1 16/4885ALDH1A1 2163/4885SMN1; SMN2 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.